Literature DB >> 12707076

Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation.

C Oliver Hanemann1, Carsten Bergmann, Jan Senderek, Klaus Zerres, Ann-Dorte Sperfeld.   

Abstract

BACKGROUND: X-linked hereditary demyelinating neuropathies (Charcot-Marie-Tooth Disease [CMTX]) caused by mutations in the connexin 32 (Cx32) gene account for approximately 10% to 20% of all hereditary demyelinating neuropathies. Mild subclinical central nervous system (CNS) involvement has been previously described, and CMTX patients with transient white matter lesions allied to CNS symptoms have very recently been described. This is of potential interest, as Cx32 is widely expressed in both peripheral nerve and the brain. PATIENTS: We describe a family with hereditary demyelinating neuropathy and transient CNS symptoms. For this study, family members underwent genotyping and detailed clinical, electrophysiological, and magnetic resonance imaging examination.
RESULTS: We present a CMTX family with a novel mutation in the Cx32 gene. Affected family members show, in addition to the classic polyneuropathy, transient and reversible white matter lesions on magnetic resonance imaging scans, correlating similarly transient CNS symptoms.
CONCLUSION: Patients with CMTX can present with transient CNS symptoms and marked white matter lesions on magnetic resonance imaging scans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707076     DOI: 10.1001/archneur.60.4.605

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  34 in total

1.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

2.  Inflammatory demyelinating CNS disorder in a case of X-linked Charcot-Marie-Tooth disease: positive response to natalizumab.

Authors:  Jochen H Weishaupt; Claudia Ganser; Mathias Bähr
Journal:  J Neurol       Date:  2012-03-13       Impact factor: 4.849

3.  X-linked Charcot-Marie-Tooth disease and multiple sclerosis.

Authors:  Y Parman; F Ciftci; M Poyraz; A M Halefoglu; A E Oge; M Eraksoy; G Saruhan-Direskeneli; F Deymeer; E Battaloglu
Journal:  J Neurol       Date:  2007-01-30       Impact factor: 4.849

4.  Functional heterotypic interactions between astrocyte and oligodendrocyte connexins.

Authors:  Laura M Magnotti; Daniel A Goodenough; David L Paul
Journal:  Glia       Date:  2011-01       Impact factor: 7.452

Review 5.  Gap junctions in inherited human disease.

Authors:  Georg Zoidl; Rolf Dermietzel
Journal:  Pflugers Arch       Date:  2010-02-07       Impact factor: 3.657

Review 6.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

Review 7.  Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Authors:  Regina M Troxell; Alison Christy
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 8.  Gap junctions in inherited human disorders of the central nervous system.

Authors:  Charles K Abrams; Steven S Scherer
Journal:  Biochim Biophys Acta       Date:  2011-08-16

9.  Human oligodendrocytes express Cx31.3: function and interactions with Cx32 mutants.

Authors:  Irene Sargiannidou; Meejin Ahn; Alan D Enriquez; Alejandro Peinado; Richard Reynolds; Charles Abrams; Steven S Scherer; Kleopas A Kleopa
Journal:  Neurobiol Dis       Date:  2008-02-15       Impact factor: 5.996

10.  Mutations in the gene encoding gap junction protein alpha 12 (connexin 46.6) cause Pelizaeus-Merzbacher-like disease.

Authors:  Birgit Uhlenberg; Markus Schuelke; Franz Rüschendorf; Nico Ruf; Angela M Kaindl; Marco Henneke; Holger Thiele; Gisela Stoltenburg-Didinger; Fuat Aksu; Haluk Topaloğlu; Peter Nürnberg; Christoph Hübner; Bernhard Weschke; Jutta Gärtner
Journal:  Am J Hum Genet       Date:  2004-06-10       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.